Takeda Licenses F-star’s Immuno-oncology Bispecific Antibody Technology

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)

Published: 25 Jul-2022

DOI: 10.3833/pdr.v2022.i7.2707     ISSN: 1756-7874

Section: Licensing



In order to boost its T-cell engager portfolio, Takeda has entered into a license agreement with F-star Therapeutics to research, develop and commercialise a bispecific antibody against an immuno-oncology target...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details